Scientists have identified a new biomarker associated with schizophrenia, as well as a potential peptide-based therapy that could target the cognitive symptoms of the disorder.
According to the latest research from Northwestern University, this discovery could represent a crucial step towards the development of the first effective therapy for cognitive deficits in schizophrenia.
Currently available drugs successfully relieve symptoms such as hallucinations and delusions, but have a limited effect on cognitive difficulties such as disorganized thinking and impaired decision-making. These symptoms significantly affect daily functioning, so many patients remain dependent on long-term therapy and care.
Tackling the Hidden Burden of Schizophrenia
Schizophrenia affects approximately 0.5% of the world’s population, including about two million people in the United States. Although antipsychotics can control impairment, it remains one of the biggest challenges.
“A large number of people with schizophrenia have difficulty fitting into society because of these cognitive deficits,” said Peter Penzes, professor of neuroscience, pharmacology, and psychiatry.
“Our discovery may contribute to solving this problem, as it lays the foundation for a completely new therapeutic approach that combines biomarker and targeted peptide therapy.”
Discovery of a New Biomarker
By detailed analysis of the cerebrospinal fluid of more than 100 subjects – including schizophrenia patients and healthy individuals – the researchers identified a circulating form of the brain protein Cacna2d1.
It was found that the concentrations of this protein are significantly reduced in patients with schizophrenia. This kind of deficit is associated with dysregulation of neural networks, specifically their excessive activation, which may represent a crucial mechanism underlying cognitive symptoms.
Synthetic Protein Shows Promising Results
To examine the therapeutic potential, a synthetic analogue of the protein SEAD1 was developed and tested in an experimental model of genetically determined schizophrenia in mice.
The results showed that even a single application leads to normalization of abnormal patterns of brain activity, along with improvements in behavioral parameters associated with the disorder. It is crucial to emphasize that no significant side effects, such as sedation or reduction of motor activity, were observed.
“This approach makes it possible to reopen the critical period for the reorganization of synaptic connections in the adult brain,” pointed out Marc Dos Santos.
“Reduced neuroplasticity is one of the key factors in the pathophysiology of schizophrenia, and its restoration may have broader therapeutic potential, including for disorders such as depression.”
Towards More Precise Treatments
The authors of the study emphasize that this discovery could pave the way for a more precise, personalized approach to treatment by integrating a diagnostic biomarker with targeted therapy. Unlike diseases such as diabetes or heart disease, psychiatric disorders do not have clearly defined biological indicators, which makes it difficult to diagnose and choose the optimal therapy.
The identification of the Cacna2d1 protein as a biomarker opens the possibility of selecting patients who are most likely to benefit from this type of intervention.
“This kind of approach could significantly increase the success of clinical trials and the effectiveness of therapy, because the drug would be used in clearly selected patients,” said Peter Penzes.
“The next step involves developing a blood biomarker to identify an appropriate subset of patients, after which peptide therapy could be administered – potentially in the form of periodic injections, similar to Ozempic therapy.”
Next Steps and Future Potential
Further research aims to optimize the structure and function of the synthetic protein and to evaluate the duration of its therapeutic effect. Additional trials are planned for people with 16p11.2 duplication syndrome, a genetic disorder associated with an increased risk of developing schizophrenia.
If the results are confirmed through clinical studies, this approach could be important not only in the treatment of schizophrenia but also in other psychiatric conditions where impaired neuroplasticity is one of the crucial pathophysiological mechanisms.
